Long duration of response with letrozole 2.5 mg (Femara®) in two trials in postmenopausal women with advanced breast cancer after anti-estrogen therapy

被引：0
|
作者：
Gardin, G
Fornasiero, A
Romieu, G
Buzzi, F
Chaudri, HA
Lassus, M
机构：
[1] Ist Nazl Ric Canc, I-16132 Genoa, Italy
[2] Osped Civile, Padua, Italy
[3] Ctr Reg Lutte Contre Canc, Montpellier, France
[4] Osped Civile S Maria, USL 12, Terni, Italy
[5] Novartis Pharma AG, AR BC2, Basel, Switzerland
[6] Novartis Pharma AG, AR BC3, Int Study Grp, Basel, Switzerland
来源：
EUROPEAN JOURNAL OF CANCER | 1998年 / 34卷
关键词：
D O I：
10.1016/S0959-8049(98)80047-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
46
引用
收藏
页码：S13 / S14
页数：2
相关论文
共 50 条
  • [1] Letrozole (FEMARA(R)), a new potent, selective aromatase inhibitor (Al): Superior to another Al, aminoglutethimide (AG), in postmenopausal women with advanced breast cancer (ABC), after relapse or progression on previous anti-estrogen therapy
    Possinger, K
    Gershanovich, M
    Campos, D
    Romieu, G
    Lurie, H
    Bonaventura, T
    Chaudri, HA
    Homberger, U
    Bischoff, MA
    [J]. EUROPEAN JOURNAL OF CANCER, 1997, 33 : 643 - 643
  • [2] INTERMITTENT ANTI-ESTROGEN THERAPY IN ADVANCED BREAST-CANCER
    STOLL, BA
    [J]. CANCER TREATMENT REPORTS, 1983, 67 (01): : 98 - 98
  • [3] Pathologic Changes in Breast Cancer After Anti-Estrogen Therapy
    Samarnthai, Norasate
    Elledge, Richard
    Prihoda, Thomas J.
    Huang, Jian
    Massarweh, Suleiman
    Yeh, I-Tien
    [J]. BREAST JOURNAL, 2012, 18 (04): : 362 - 366
  • [4] Pathologic changes in breast cancer after anti-estrogen therapy
    Samarnthai, Norasate
    Elledge, Richard
    Huang, Jian
    Massarweh, Suleiman
    Yeh, I-Tien
    [J]. FASEB JOURNAL, 2010, 24
  • [5] Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?
    Bronte, Giuseppe
    Rocca, Andrea
    Ravaioli, Sara
    Puccetti, Maurizio
    Tumedei, Maria Maddalena
    Scarpi, Emanuela
    Andreis, Daniele
    Maltoni, Roberta
    Sarti, Samanta
    Cecconetto, Lorenzo
    Pietri, Elisabetta
    De Simone, Valeria
    Asioli, Silvia
    Amadori, Dino
    Bravaccini, Sara
    [J]. BMC CANCER, 2018, 18
  • [6] Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?
    Giuseppe Bronte
    Andrea Rocca
    Sara Ravaioli
    Maurizio Puccetti
    Maria Maddalena Tumedei
    Emanuela Scarpi
    Daniele Andreis
    Roberta Maltoni
    Samanta Sarti
    Lorenzo Cecconetto
    Anna Fedeli
    Elisabetta Pietri
    Valeria De Simone
    Silvia Asioli
    Dino Amadori
    Sara Bravaccini
    [J]. BMC Cancer, 18
  • [7] Is androgen receptor useful to predict the efficacy of anti-estrogen therapy in advanced breast cancer?
    Rocca, Andrea
    Bronte, Giuseppe
    Ravaioli, Sara
    Puccetti, Maurizio
    Tumedei, Maria Maddalena
    Scarpi, Emanuela
    Maltoni, Roberta
    Sarti, Samanta
    Cecconetto, Lorenzo
    Bedei, Lucia
    Fedeli, Anna
    Andreis, Daniele
    Pietri, Elisabetta
    Calistri, Daniele
    Amadori, Dino
    Bravaccini, Sara
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] Letrozole reduces spread of early breast cancer after tamoxifen therapy in postmenopausal women
    不详
    [J]. ONCOLOGY-NEW YORK, 2004, 18 (09): : 1156 - +
  • [9] Breast Density Change as a Predictive Surrogate of Adjuvant Anti-estrogen Therapy Response in Estrogen Receptor Positive Breast Cancer
    Kim, J. S.
    Han, W.
    You, J. M.
    Shin, H. C.
    Ahn, S. K.
    Moon, H. G.
    Noh, D. Y.
    Cho, N.
    Moon, W. K.
    Park, I. A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 : S133 - S133
  • [10] A multicenter study of pre-operative treatment with Femara® (Letrozole) for optimal duration of treatment in postmenopausal women with ER and/or PgR positive breast cancer.
    Paepke, S
    Bouterfa, H
    Wallwiener, D
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 290 - 290
12345